Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company whose news flow centers on the development of immunotherapy medicines based on halogenated xanthenes, particularly its lead molecule rose bengal sodium. As an OTCQB-traded company, Provectus regularly issues updates on preclinical and clinical research, investor events, and corporate initiatives that shape the outlook for its investigational programs.
News about Provectus often highlights progress with PV-10, the company’s rose bengal sodium-based investigational cancer immunotherapy. Recent announcements have covered preclinical studies in head and neck squamous cell carcinoma, orthotopic bladder cancer models using oral and intravesical PV-10, and mechanistic work showing activation of the STING immune pathway and enhanced T-cell responses in vaccine settings. These items provide insight into how the company is exploring PV-10 across oncology and immunology applications.
Investors and researchers following PVCT can also expect updates on wound healing and dermatology research, such as non-clinical data on full-thickness cutaneous wounds, as well as ophthalmology developments through the VisiRose founded entity focused on rose bengal sodium-based eye therapies. Additional news items include announcements of annual stockholder meetings, investor webinars, and conference calls, which offer company updates and access to management presentations.
This PVCT news page aggregates these disclosures in one place, making it easier to review Provectus’s latest scientific publications, collaboration highlights, and corporate communications. For anyone tracking the evolution of its rose bengal sodium platform across oncology, dermatology, ophthalmology, infectious diseases, and tissue repair research, this feed provides an organized view of the company’s reported milestones and ongoing activities.
Provectus (OTCQB: PVCT) will hold its 2026 Annual Meeting of Stockholders on June 18, 2026 at 4:00 p.m. ET at Perkins Place, 525 Portland Street, Knoxville, Tennessee.
Perkins Place is Provectus’s planned new headquarters: a 22,941 sq ft renovated building on 3.23 acres, reacquired in fall 2025 via a partnership with the East Tennessee Foundation. The move is intended to help manage costs and allow future expansion.
Provectus (OTCQB: PVCT) highlighted independent porcine preclinical data showing PV-10 (rose bengal sodium) in a Pluronic hydrogel shifted wound immunity toward a pro-regenerative state. At day 120 post-burn PV-10 increased pan-macrophage and CD206 expression (p=0.0034; p=0.0277) and reduced CD3+ T cells (p=0.0360) versus saline, with no rise in 4-HNE oxidative markers.
The study found measurable activity after repeated topical dosing without controlled green-light activation, and noted formulation/dosing adjustments may further differentiate effects.
Provectus (OTCQB: PVCT) reported independent preclinical research (Oct 9, 2025) showing PV-10 (rose bengal sodium) activates the STING pathway, stabilizing STING dimerization, upregulating pro-inflammatory cytokines/chemokines, and boosting IFN‑gamma from antigen-primed T cells. The study suggests PV-10 could serve as a differentiated vaccine adjuvant alternative to aluminum salts, emulsions, saponins, and nucleic acid fragments and may help ~10% of vaccine non-responders for hepatitis B.
Company highlights market optionality: vaccine adjuvant market projected to exceed $2B by 2030, global vaccine sales >b$70B by 2030, oncology vaccine market >b$10B by 2032, and immune checkpoint therapies >b$40B.
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched a preclinical study of its lead drug PV-10 for bladder cancer treatment. The study, conducted by TD2, will evaluate both oral and intravesical monotherapy applications, as well as combination therapy with an anti-PD-1 checkpoint inhibitor.
The research aims to generate translational data to guide future clinical development and support broader immuno-oncology applications. Results are expected in Q1 2026. The study's findings will potentially enable expansion of PV-10's investigational new drug application for both site-specific and systemic administration.
Provectus Biopharmaceuticals (OTCQB: PVCT) announced the publication of preclinical research on PV-10 for head and neck squamous cell carcinoma (HNSCC) in Molecular Cancer Therapeutics. The research, conducted by Dr. Christine Chung's team at Moffitt Cancer Center, revealed novel mechanistic findings about PV-10's ability to trigger immunogenic cell death in HNSCC through endoplasmic reticulum stress and apoptosis.
The company plans to initiate a Phase 1 trial of intratumoral PV-10 in pre-operative penile squamous cell carcinoma at Moffitt Cancer Center later in 2025. PV-10 is Provectus's investigational cancer immunotherapy formulated from pharmaceutical-grade rose bengal sodium (RBS).
Provectus Biopharmaceuticals (OTCQB: PVCT) announced a $3 million seed financing round for its spinoff company, VisiRose. VisiRose is a clinical-stage biotechnology company focused on developing Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) for treating infectious keratitis and other eye infections. RB-PDAT uses Provectus's bioactive synthetic small molecule, Rose Bengal Sodium (RBS), combined with a light-based medical device from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute.
The financing will support several key initiatives: preparing for a pre-IND submission meeting with the FDA for RB-PDAT, submitting an IND application for the investigational eye drug PV-305, manufacturing an initial clinical supply of PV-305, and applying for Small Business Innovative Research grant funding. Dominic Rodrigues, Vice Chairman of Provectus and Acting CEO of VisiRose, expressed optimism about advancing VisiRose's ophthalmology drug pipeline.
VisiRose's website is accessible at: visirose.com
Provectus Biopharmaceuticals (OTCQB: PVCT) has launched VisiRose, Inc., its first Founded Entity, focusing on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT) for treating infectious keratitis and serious eye infections. The University of Miami is a minority shareholder in VisiRose.
The treatment combines Provectus's pharmaceutical-grade Rose Bengal Sodium (RBS) API with a light-based medical device developed at the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute. RB PDAT is designed to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms.
Provectus Biopharmaceuticals (OTCQB: PVCT) has scheduled its Fourth Quarter 2024 Investor Update webinar via Zoom for Thursday, November 14, 2024, at 2 p.m. EST. Interested participants can access the conference call by registering in advance through the provided Zoom registration link.
Provectus Biopharmaceuticals (OTCQB: PVCT) has announced a conference call scheduled for Thursday, November 14, 2024 at 2 p.m. EST. The purpose of the call is to provide Company updates. Provectus has stated that the conference call details will be shared closer to the event date. This announcement indicates that the company is planning to communicate important information to its stakeholders, which could potentially include updates on financial performance, research and development progress, or other significant business developments.